Business Context and Reporting Period
This Form 8-K filing by Dare Bioscience, Inc. (DARE) was submitted on January 24, 2023. The report addresses a specific regulatory event regarding the company's listing status on the Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on compliance with exchange listing rules.
Material Changes
The primary event reported is the resolution of a compliance issue with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price. Dare Bioscience regained compliance after its common stock closing bid price remained at or above $1.00 per share for a minimum of 10 consecutive business days. Nasdaq Listing Qualifications has officially closed the matter.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks or contingencies beyond the resolution of the minimum bid price deficiency.
Investor Verification Checklist
- Verify the current trading price of DARE common stock to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review recent 10-Q or 10-K filings for the company's actual financial position, as this 8-K contains no financial metrics.
- Monitor future Nasdaq communications for any new compliance notices regarding listing standards.